Individualized Treatment Plans in ALL: Effective Management Strategies to Optimize Patient Outcomes

MODULE ALL-103

Supported by educational grants from Amgen and Baxalta

TITLE - Individualized Treatment Plans in ALL: Effective Management Strategies to Optimize Patient Outcomes

TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Oncology Pharmacists, Pharmacy Directors, Chief Pharmacy Officers, Oncology Nurses and Nurses

LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Oncology Pharmacists, Pharmacy Directors, Chief Pharmacy Officers, Oncology Nurses and Nurses, along with other healthcare practitioner participants will be able to:

  1. Discuss acute lymphoblastic leukemia (ALL) subtypes, classifications, and other individualized measures in the development of a personalized plan of care
  2. Identify non-pharmacologic therapeutic options and discuss their utilization in combination with traditional and novel therapies to reduce symptoms and improve quality of life for ALL patients
  3. Discuss early decision-making strategies to improve outcomes in patients with ALL
  4. Review the challenges associated with treating ALL in patients and common barriers to treatment adherence
  5. Identify support resources and describe strategies to educate ALL patients on the importance of treatment and appropriate management of their disease

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.5 hours (0.05CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-17-004-H01-P

Knowledge Based Activity

Course release date 2/8/2017

Course expires 2/8/2020

Nursing continuing education credit

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 0.5 hour of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Course release date 2/16/2017

Course expires 2/16/2019

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-17-004-H01-P 0.05 CEUs February 08, 2017 - February 08, 2020
0535-0000-17-004-H01-N 0.5 hours of CNE February 16, 2017 - February 16, 2019